Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI assessment and claim are consistent with the provided boxed warning/warnings regarding fatal hepatotoxicity, possible preceding non-specific symptoms, close monitoring, and increased risk in children under 2 years. No direct contradictions were identified.
Category Scores
Accurate Statements
Hepatic failure resulting in fatalities has occurred in patients receiving divalproex sodium/valproic acid.
BOX WARNING — HEPATOTOXICITY; WARNINGS — Hepatotoxicity (fatal hepatic failure incidents in patients receiving valproic acid and derivatives).
It may be preceded by non-specific symptoms and requires close monitoring.
BOX WARNING — HEPATOTOXICITY (non-specific symptoms; patients should be monitored closely); WARNINGS — Hepatotoxicity (monitoring for symptoms).
Especially in children under 2 years.
BOX WARNING — HEPATOTOXICITY (children under 2 at considerably increased risk); WARNINGS — Hepatotoxicity; Use in Specific Populations (Pediatric Use).
Unsupported Statements
Contradictions
Important Omissions
The label text provided includes additional specifics that are not stated in the claim/assessment: (1) that events usually occur during the first six months of treatment, (2) the specific list of non-specific symptoms (e.g., malaise, weakness, lethargy, facial edema, anorexia, vomiting) and possible loss of seizure control in epilepsy, (3) liver function tests should be performed prior to therapy and at frequent intervals thereafter—especially during the first six months, and (4) guidance to discontinue immediately in the presence of significant hepatic dysfunction.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI did not suggest dosing changes or negate safety guidance; it aligned with the label’s core warning elements (fatal hepatic failure, age-based increased risk, non-specific symptom monitoring). However, it omitted several label-specific monitoring/timing/discontinuation details.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted label-specific details (first six months timing, symptom list, liver function test schedule, and discontinuation guidance).
Suggested Improvement
Include the label’s timing (first six months), specify that liver function tests should be done prior to therapy and at frequent intervals (especially during the first six months), and note the instruction to discontinue immediately with significant hepatic dysfunction; optionally include the symptom examples listed in the boxed warning.